Piramal Pharma Solutions has signed a Memorandum of Understanding (MoU) with IntoCell to expand its capabilities in the development and manufacturing of Antibody-Drug Conjugates (ADCs). This collaboration aims to enhance Piramal’s Payload-Linker platform and bio-conjugate innovations, speeding up delivery of next-generation targeted therapies.
Piramal Pharma Solutions (PPS), a global contract development and manufacturing organization (CDMO), has formalized its partnership with IntoCell, a specialist in drug conjugate technologies, officially expanding its Payload-Linker platform and bioconjugate capabilities. This MoU focuses on leveraging complementary expertise to accelerate the development of ADCs—an advanced class of targeted cancer therapies combining antibodies with potent cytotoxic agents.
With this collaboration, PPS enhances its integrated drug conjugation services, from early bench research to commercial GMP manufacturing, combining PPS’s manufacturing scale and regulatory experience with IntoCell’s novel linker and payload technologies. The partnership underpins PPS’s commitment to innovation in the biologics space, addressing increasing demand for customized, precision oncology drugs.
Through an accelerated drug development approach branded as ADCelerate™, PPS aims to deliver clinical drug substances and products faster to market, minimizing timelines without compromising quality or compliance.
Key Highlights:
-
MoU signed between Piramal Pharma Solutions and IntoCell for ADC development.
-
Expansion of Payload-Linker platform and bioconjugate technology capabilities.
-
Integrated services spanning preclinical development to GMP manufacturing.
-
Focus on accelerating delivery of targeted cancer therapies.
-
ADCelerate™ program offers rapid phase I-ready drug substance and product.
Partnership strengthens PPS’s leadership in biologics and precision oncology manufacturing.
Sources: Piramal Pharma Solutions Press Release, PR Newswire